Boston Bio life Workshop - Quad Video HALO will be a participating sponsor at this workshop. This two-day course allows the participants to experience a comprehensive and intensive learning opportunity focusing on regenerative medicine techniques and their clinical applications in pain management. Attendees are primarily interventional pain management specialists, orthopedic physicians, rehabilitation specialists, sports medicine physicians, and osteopathic doctors. Aside from presenting QVH in the forum setting before attendees, SPIN’s QVH v.3 will be featured as an integral part of the “hands on” workshops involving stem cell/spine injection procedures utilizing Quad Video Halo/ISP technologies. Each attending physician will receive a QVH recording of the cadaver procedure. Representing QVH will be SPIN CEO Dr. Donovan, QVH President, David Spencer, Matt DeGaetno, VP Sales and Marketing and Tim Donovan, VP of Business Development.

Dr. Donovan stated; “This will be the second leg of the Boston Bio Life tour QVH has sponsored. In July of this year, the QVH v.3 was introduced for the first time at the BBL, Boston Workshop to interested physicians. Of the estimated 80 Doctors in attendance at the Boston venue, we have entered into many NDA’s for possible QVH sales. As of last week, the Company now has the ability to facilitate third party financing for prospective purchasers, both loan and lease.

Donovan went on to say: “The boutique BBL Workshops around the country have a broad following of innovative doctors who grasp the need for continuously updating of new technologies. BBL’s target market is that of fast growing regenerative medicine, particularly for pain, which in most cases require a fluoroscopic C-Arm for accurate delivery. After our presentation in front of attendees, each attendee will have an opportunity to see the QVH 'in action' creating real time video documentation at their hands working with human cadavers."

About Boston Bio Life

Boston BioLife is an organization that provides workshops that specialize in educational programs in the life sciences technologies for physicians and scientists interested in learning regenerative medicine. Our mission is to offer a “boutique style” forum, in which, we facilitate the understanding of emerging life sciences technologies by scientists and healthcare providers in a position to make an impact on people’s lives. Boston BioLife is proud to introduce companies and innovations that may not otherwise be recognized and to provide scientific studies and background that ensures validation.

We are a medical finance and technology company facilitating diagnostic services for patients who have sustained spine injuries. We deliver turnkey solutions to spine surgeons, orthopedic surgeons and other healthcare providers that provide necessary and appropriate treatment of musculo-skeletal spine injuries. Our services help reduce the financial burden on healthcare providers that provide patients with early-stage diagnostic testing and non-invasive surgical care, preventing many patients from being unnecessarily delayed or inhibited from obtaining needed treatment. We believe that our services and technology brings strong transparency and impartiality to all parties involved.

Forward-Looking Statements: This press release includes forward-looking statements as determined by the U.S. Securities and Exchange Commission (the "SEC"). All statements, other than statements of historical facts, included in this press release that address activities, events, or developments that the company believes or anticipates will or may occur in the future are forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to acquire and develop specific projects, the ability to fund operations, healthcare service demands, changes in healthcare practices, government regulation, and other factors over which the company has little or no control. The company does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the warnings and cautionary statements contained in the company's recent filings with the SEC.